ABL1 and prostate cancer: These analyses showed that (i) ABL1 had lower statistically significant levels (with log2 2−ΔΔCt < −1) in both androgen receptor-positive cell lines (22RV1 and LNCaP), but higher levels in the two androgen receptor-negative cell lines, although these values were not statistically significant; (ii) the EP300, FYN, MYC, PSMB2, and SRPK2 levels increased in all four prostate cancer cell lines, although the EP300 and FYN levels were not statistically significant.